This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Nanoparticle administration of latanoprost

Nanoparticle administration of latanoprost
Reviewed by Graham Wallace

1 December 2013 | Graham Wallace | EYE - Glaucoma

Glaucoma is a progressive optic neuropathy characterised by increased ocular pressure and loss of retinal ganglion cells. Conventional drug therapy with eye drops to reduce intraocular pressure (IOP) has variable bioavailability and can lead to ocular surface disease. In this study poly(lactide)/monomethoxy-poly(ethyleneglycol) (PLA-PEG) nanoparticles (NP) were developed as a controlled drug delivery system. Latanoprost-loaded NP was administered to the subconjunctival space in rabbits with free LA and empty NP were given to two other groups of animals as controls. Aqueous humour levels of LA were measured by HPLC, and showed the drug released from NP was sustained over 14 day period. LA release from NP induced a significant hypotensive effect while the IOP remained the same in the other groups. No ocular inflammation was seen in the NP treated group. Nanoparticle technology is advancing at a significant rate targeting tumour and immune cells. The use of such systems for slow and controlled release of drug in ocular conditions is a potentially important step forward in treatment of disease. 

Biodegradable nanoparticles for controlled subconjunctival delivery of latanoprost acid: in vitro and in vivo evaluation.
Giarmoukakis A, Labiris G, Sideroudi HA, et al.
EXPERIMENTAL EYE RESEARCH
2013;112;29-36.
Share This
CONTRIBUTOR
Graham Wallace

Birmingham and Midland Eye Centre, Birmingham, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency